Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | GRIFFIN updates: D-RVd vs RVd in transplant-eligible patients with newly diagnosed multiple myeloma

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, summarizes the updated results of the GRIFFIN trial evaluating the addition of daratumumab to lenalidomide, bortezomib and dexamethasone (D-RVd) and autologous stem cell transplant (ASCT) to induction, consolidation and maintenance therapy versus lenalidomide, bortezomib and dexamethasone (RVd) with ASCT in patients with newly diagnosed multiple myeloma (NCT02874742). The study reported an impressive improvement in response rates (RR) and measurable residual disease (MRD) rates, especially during consolidation and maintenance therapy for patients in the daratumumab arm. In addition, at a median follow-up of three years, the progression-free survival (PFS) rates were approximately 90% for patients treated with quadruplet therapy versus 80% for patients treated with triplet therapy. Importantly, the addition of daratumumab did not result in a higher side effect rate. The results from this trial provide strong evidence for the clinical benefit of quadruplet therapy in this patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.